Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aptevo Therapeutics

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
From Aptevo Therapeutics
Via AccessWire
Topics Retirement
Tickers APVO
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit
From Aptevo Therapeutics
Via AccessWire
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
From Aptevo Therapeutics
Via AccessWire
Topics Death Intellectual Property
Tickers APVO
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
From Aptevo Therapeutics
Via AccessWire
Tickers APVO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.